Melbourne lab new hub for exosome research, development and production
Posted: 2 December INOVIQ Limited has announced that it has transferred all research, development and manufacturing for EXO-NET to its Melbourne facility. The company has indicated that this ‘exosome core facility’ will allow INOVIQ to streamline its research…
Immutep Limited has signed a Clinical Trial Collaboration and Supply Agreement with Merck Group and Pfizer for a new Phase I clinical study in urothelial cancer patients called INSIGHT-005.
Posted: 29 November Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immuno therapies for cancer and autoimmune disease, is pleased to announce it has signed a Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany…
Levelling up advanced manufacturing at RMIT
Posted: 29 November RMIT’s Advanced Manufacturing Precinct (AMP) is expanding to include 3 cutting-edge facilities that will deliver 21st century manufacturing. The new, expanded precinct will remain based at the City Campus site and accommodate the original AMP now known as…
U.S. Food and Drug Administration approves CSL’s HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B
Posted: 24 November Global biotechnology leader CSL announced that the U.S. Food and Drug Administration (FDA) approved HEMGENIX® (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy for appropriate adults with hemophilia B. HEMGENIX is approved for the…
Applications Open: CSIRO ON Prime
Posted: 23 November Closes: 17 February 2023 ON Prime is a free program designed to help research teams of two to five people take their projects to the next level through customer discovery activities and more. We work…
2022 BioMelbourne Network Annual General Meeting wrap
Posted: 18 November 2022 The 2022 BioMelbourne Network Annual General Meeting and Networking Event was held on Thursday 17 November in person and online. Honorary Life Membership awards BioMelbourne Network bestows Honorary Life Membership awards to Members whose…
4DMedical Debuts “XV Scanner,” Most Advanced Lung Scanning Technology in Decades At RSNA
Posted: 18 November 4DMedical will unveil the “XV Scanner,” a breakthrough lung scanning device that integrates fluoroscopy with advanced analytics software at the 2022 annual meeting of the Radiological Society of North America (RSNA) in Chicago. The XV…
Phase 2 trial of ChulaCov19 BNA159 mRNA Vaccine to start in Australia
Posted: 18 November ChulaCov19 BNA159 is a COVID-19 mRNA vaccine developed by Chulalongkorn University and produced by BioNet • ChulaCov19 mRNA vaccine was found safe and immunogenic for primary immunization in clinical trials in Thailand. • The Australian…
ARCS Signature Program
Posted: 16 November 2022 Closes: 13 February 2023 The ARCS Signature Program is designed for senior executives and emerging leaders who are working in the med tech, biotech and pharmaceutical sectors. This includes those who are part of…
Backing business events to support jobs and innovation
Posted: 15 November The City of Melbourne has doubled its funding to support conferences, workshops and other business events – bringing more people together to drive innovation and boost the economy. An augmented reality festival, sustainable tech pitch…
Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC
Posted: 11 November Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced compelling new clinical data from the TACTI-002 all-comer PD-L1 Phase II trial evaluating Immutep’s lead product candidate, eftilagimod alpha…
